Impact of Plerixafor Use at Different Peripheral Blood CD34+ Thresholds on Autologous Stem Cell Collection in Patients with Multiple Myeloma.
Patients with multiple myeloma planning for autologous stem cell transplant must undergo autologous stem cell mobilization, however many unfortunately do not obtain an adequate collection yield. Despite the availability of plerixafor, widespread and uniform use is limited by its cost, and consequently, many institutions have adopted various risk-adapted algorithms. We report our mobilization experience as we have modified our plerixafor algorithm to a more liberal one, expecting greater collection efficiency and mobilization success with higher plerixafor use. A total of 344 mobilization attempts were analyzed, occurring over three time periods and utilizing three different peripheral blood CD34+ cell counts to guide plerixafor use: CD34+ < 15/µL (n = 66), < 20/µL (n = 130), < 40/µL (n = 148). The primary endpoints were to evaluate change in mean plerixafor utilization and apheresis days and to assess the impact on overall mobilization costs. Secondary endpoints were to describe the impact of lenalidomide use on mobilization and to evaluate the rates of mobilization failure. We demonstrate that mean plerixafor utilization increased from 1.32 to 1.65 to 1.74 doses per mobilization (p = 0.026) while mean apheresis days decreased from 2.15 to 2.17 to 1.89 days per mobilization for the < 15/µL, < 20/µL, < 40/µL cohorts (p = 0.011), respectively. The combined cost of plerixafor and apheresis procedures are nearly similar at a threshold of 40/µL compared to 15/µL, while saving 26 apheresis days per 100 patients. In general, there were low rates of mobilization failure across all thresholds. Patients who received more than 6 cycles of lenalidomide demonstrated impaired mobilization, and required more apheresis sessions (p < 0.013) and plerixafor utilization (p < 0.001) to reach target stem cell yields.. Overall, using plerixafor in MM patients with a day 4 pCD34 count of <40/µL is a reasonable and cost-effective strategy to optimize apheresis utilization.